A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)

Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
11/2004
11/24/2004	CN1176651C N-(3-benzofuryl) urea derivative
11/24/2004	CN1176647C 间苯二酚衍生物 Resorcinol derivatives
11/23/2004	US6822102 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2 mediated disorders
11/23/2004	US6822100 Reacting n-sulfonyl-3-vinylindole with ruthenium complex in presence of ethyl diazoacetate and toluene; psychological, sexual, and eating disorders
11/23/2004	US6822097 Compounds and methods of uses
11/23/2004	US6822087 For anti-asthma/allergy/hypereosinophilia/inflammation/ cancer/tumor drugs; gene expression inhibition
11/23/2004	US6821987 4-substituted by azolylureido-phenoxy, or phenylthio; antitumor agents; treating diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis,
11/23/2004	US6821984 Ring fused pyrazole derivatives as CRF antagonists
11/23/2004	US6821973 Compounds
11/23/2004	US6821971 For prophyalxis of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease (ibs), septic shock, cardiopulmonary dysfunction, acute respiratory disease, cachexia
11/23/2004	US6821966 Antiinflammatory agents
11/23/2004	US6821965 Important in disease or medical conditions such as inflammation and immunoregulation
11/23/2004	US6821964 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation
11/23/2004	US6821962 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases
11/23/2004	US6821956 Oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes.
11/23/2004	US6821950 Antagonist of a g protein-coupled receptor, which has no agonist activity, and which has a cyclic or constrained acyclic structure
11/23/2004	US6821549 Contacting stent with a coating solution containing a coating material to be deposited on surface of stent; inserting thread through the lumen of the stent; producing relative motion between stent and thread to remove coating material
11/23/2004	CA2329788C Quinoline derivatives
11/23/2004	CA2326970C Acetylene derivatives as anti-inflammatory/analgesic agents
11/23/2004	CA2231803C Lipid extract having anti-inflammatory activity
11/23/2004	CA2171446C Pseudo- and non-peptide bradykinin receptor antagonists
11/23/2004	CA2161346C Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/23/2004	CA2135768C Indolocarbazole imides and the use thereof
11/18/2004	WO2004099205A1 Azaindole compounds as kinase inhibitors
11/18/2004	WO2004099190A1 Novel substituted benzimidazole derivatives
11/18/2004	WO2004099150A2 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
11/18/2004	WO2004099130A2 1,2-diarylimidazoles useful as inhibitors of cox
11/18/2004	WO2004099127A1 Novel compounds as kinase inhibitors
11/18/2004	WO2004099126A1 N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN α4 ANTAGONISTS
11/18/2004	WO2004098714A1 Methods for treating sinus headache
11/18/2004	WO2004098634A2 Protein arginine n-methyltransferase 2 (prmt-2)
11/18/2004	WO2004098606A1 Composition comprising a pde4 inhibitor and shuil-1r ii
11/18/2004	WO2004098596A1 Composition comprising roflumilast and il-1 trap
11/18/2004	WO2004098590A1 4-bromo-5- (2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl) eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
11/18/2004	WO2004098589A1 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
11/18/2004	WO2004098585A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
11/18/2004	WO2004098578A2 Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
11/18/2004	WO2004098575A1 Ultraviolet-shielding type patch
11/18/2004	WO2004073593A3 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications
11/18/2004	WO2004071381A3 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds
11/18/2004	WO2004038406A3 Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42)
11/18/2004	WO2004002528A9 Compositions and methods for therapeutic treatment
11/18/2004	WO2003038043A3 Combinations of dr5 antibody and other therapeutic agents
11/18/2004	WO2003037913A3 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/18/2004	US20040230064 Novel labeled resiniferatoxin derivatives
11/18/2004	US20040230037 Chemokine receptor materials and methods
11/18/2004	US20040229923 Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying
11/18/2004	US20040229887 Novel imidazopyrimidinyl and imidazopyri dinyl derivatives
11/18/2004	US20040229882 dipeptide or tripeptide MC-1R and MC-4R agonists
11/18/2004	US20040229879 CRF receptor antagonists and methods relating thereto
11/18/2004	US20040229876 Quinoline derivatives and quinazoline derivatives having azolyl group
11/18/2004	US20040229875 Administering compounds such as 4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid dimethylamide for therapy of transplant rejection, melanoma, or a cancer selected from colon, breast, lung, kidney, ovary, pancreas, CNS, or cancer of the gastric tract
11/18/2004	US20040229872 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity
11/18/2004	US20040229870 Certain alkylene diamine-substituted heterocycles
11/18/2004	US20040229859 Beta-amino acid compounds as integrin antagonists
11/18/2004	US20040229851 2-Propylidene-19-nor-vitamin D compounds
11/18/2004	US20040229834 PREFERENTIAL CLASSIFICATON BETWEEN CANCER CELLS; OBTAIN SAMPLE, MONITOR SAMPLE FOR PREFERENTIAL ENZYMATIC ACTIVITY, EVALUATE DIFFERENTIATED CELLS; for of detecting presence or absence or level of a polynucleotide sequence encoding heparanase in a biological sample
11/18/2004	US20040229833 Therapeutic use of cis-element decays in vivo
11/18/2004	US20040229796 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
11/18/2004	US20040229795 For oncological diseases and diseases accompanying neovascularization, immune complex-mediated and autoimmune diseases, viral infections, fibrotic and granulomatous diseases, allergic diseases, degenerative diseases of the nervous system and arteriosclerosis
11/18/2004	US20040229790 Substance having an activity which modulates or inhibits proliferation of AILIM(activation inducible lymphocyte immunomodulatory molecule)-expressing cells or production of a cytokine; for treatment of rheumatoid arthritis, osteoarthritis
11/18/2004	US20040229788 Cell surface molecule mediating cell adhesion and signal transmission
11/18/2004	US20040229783 Inhibiting an inflammatory response in a tissue comprising leptin receptor positive cells, by administering to the tissue an agent that inhibits the signaling activity of the leptin receptor that mediates intestinal inflammation, thereby inhibiting the inflammatory response in the tissue
11/18/2004	US20040228857 administration of a human or humanized antibody expressed and glycosylated in a chinese hamster ovaries (CHO) cell expression system to treat T-cell mediated disorders, autoimmune disorders, cancer and infections; vasculitis, arthritis, lupus, psoriasis, multiple sclerosis, graft versus host disease
11/18/2004	US20040228855 Method for treating symptoms of diabetes
11/18/2004	US20040228808 Inhaling formulation providing analgesia to patient; contains one rapid-onset opioid and a sustained-effect opioid; avoiding toxicity while achieving analgesia, side effect occurs before the onset of toxicity; dispensers
11/18/2004	US20040228807 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
11/18/2004	US20040228803 Sleeve and micro-encapsulated topical analgesic for pain relief
11/18/2004	US20040228798 A conjugated drug contains virus-like particle is joined to the antigen by a biotin molecule; bioassay; inhibiting HIV infection, viral infection
11/18/2004	CA2524891A1 Ultraviolet-shielding type patch
11/18/2004	CA2524889A1 1,2-diarylimidazoles useful as inhibitors of cox
11/18/2004	CA2524593A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
11/18/2004	CA2524379A1 Methods for treating sinus headache
11/18/2004	CA2524318A1 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivates and related compounds as bradykinin b1 receptor antagonists for the treatment of inflamatory diseases
11/18/2004	CA2524274A1 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
11/18/2004	CA2524269A1 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
11/18/2004	CA2523922A1 Azaindole compounds as kinase inhibitors
11/18/2004	CA2523235A1 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
11/17/2004	EP1477497A1 Humanized immunoglobulins and their production and use
11/17/2004	EP1477490A1 Pyrrolopyrimidine derivative
11/17/2004	EP1477489A1 Pyrrolopyrimidine derivatives
11/17/2004	EP1477483A1 Vitamin d3 derivatives and remedies using the same
11/17/2004	EP1477482A1 Novel phenylalanine derivative
11/17/2004	EP1477479A1 Process for the preparation of the D-(-)-tartrate salt of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-YL)-1-propanol
11/17/2004	EP1477472A1 Substituted phenylalkanoic acid derivative and use thereof
11/17/2004	EP1477187A1 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
11/17/2004	EP1477183A1 Botulinum toxins for modulating cholinergic controlled secretions
11/17/2004	EP1477182A1 Novel analgesics
11/17/2004	EP1477175A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
11/17/2004	EP1477165A2 Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
11/17/2004	EP1476752A1 Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
11/17/2004	EP1476574A2 RNA INTERFERENCE MEDIATED INHIBITION OF TYPE 1 INSULIN-LIKE GROWTH FACTOR RECEPTOR (IGF-1R) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/17/2004	EP1476545A2 Aggrecanase molecules
11/17/2004	EP1476541A2 Novel cytokine zcytor17 ligand
11/17/2004	EP1476540A1 Methods for producing gama delta t cells
11/17/2004	EP1476471A1 Nutraceuticals for the treatment, protection and restoration of connective tissues
11/17/2004	EP1476469A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
11/17/2004	EP1476461A2 Immune-modulating peptide made of s. aureus enterotoxin b
11/17/2004	EP1476460A2 A nucleic acid encoding a g-protein-coupled receptor; and uses thereof
11/17/2004	EP1476458A2 Rna interference mediated inhibition of platelet derived growth factor (pdgf) and platelet derived growth factor receptor (pdgfr) gene expression using short interfering nucleic acid (sina)

1 ... 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 ... 1272